Gibson Dunn Advises XOMA on Acquisition of Turnstone Biologics Corp.
Firm News | June 30, 2025
Gibson Dunn is representing XOMA Royalty Corporation, a publicly traded biotech royalty aggregator, on its acquisition of Turnstone Biologics Corp.
Turnstone Biologics Corp. is a biotechnology company that was focused on developing new medicines to treat and cure patients with solid tumors.
Gibson Dunn regularly advises life sciences companies and investors on complex acquisitions in the biotechnology sector.
The Gibson Dunn corporate team includes Branden Berns and Chad Kang. Team members advising on additional aspects of the transaction include Jennifer Sabin (Tax) and Sean Feller and Spencer Bankhead (Employee Benefits).